10-K: Vycor Medical Narrows Losses, Faces Going Concern Doubts

Vycor Medical reported increased revenue and reduced net losses in 2025, driven by international growth, but faces substantial doubt about its ability to continue as a going concern.

Summary

• Total revenue increased by 17.2% to $1,863,400 in 2025 from $1,589,324 in 2024.
• Vycor Medical division revenue grew by 18% to $1,796,070, primarily due to strong international demand in Europe.
• NovaVision division revenue decreased by 8% to $67,330.
• Net loss significantly reduced to $72,426 in 2025 from $107,200 in 2024.
• Operating income improved to $33,900 in 2025 from an operating loss of $9,145 in 2024.
• Gross margin for Vycor Medical decreased to 83% in 2025 from 89% in 2024, attributed to validation, shipping, higher manufacturing costs, and a higher international sales mix.
• The company has a working capital deficiency of $4,218,046 as of December 31, 2025, including $3,658,382 in related party liabilities.
• Cash used in operating activities was $13,471 in 2025, a shift from $60,110 provided by operating activities in 2024.
• The company engaged Maxim Group LLC in August 2024 to assist with strategic acquisitions, partnerships, and a potential uplisting to a US exchange.
• Substantial doubt exists regarding the company's ability to continue as a going concern due to accumulated losses, insufficient cash flows, and the working capital deficiency.
• A term note for $300,000 to EuroAmerican Investment Corp., with $569,030 in accrued interest, matures on June 30, 2026, with no certainty of further extension.
• The company's board lacks independent directors, and the audit committee comprises the entire board, leading to a material weakness in internal controls.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a highly concerning filing due to the explicit going concern warning, worsening working capital deficit, negative operating cash flow, and significant corporate governance issues, despite some revenue growth.

Positives

• Overall revenue increased by 17.2% year-over-year, reaching $1,863,400 in 2025.
• Vycor Medical division revenue grew by 18% to $1,796,070, driven by strong international demand, particularly in Europe.
• The company achieved an operating income of $33,900 in 2025, a significant improvement from an operating loss of $9,145 in 2024.
• Net loss was reduced to $72,426 in 2025 from $107,200 in 2024.
• NovaVision's gross margin improved to 93% in 2025 from 91% in 2024.
• The company has established cybersecurity policies and processes, including third-party support, MFA, and cyber risk insurance, and has not identified any material cybersecurity risks.

Negatives

• The company has a substantial working capital deficiency of $4,218,046 as of December 31, 2025, which increased from $3,876,929 in 2024.
• Cash flow from operating activities turned negative, with $13,471 used in 2025 compared to $60,110 provided in 2024.
• NovaVision division revenue decreased by 8% to $67,330 in 2025.
• Vycor Medical's gross margin decreased to 83% in 2025 from 89% in 2024 due to higher production and shipping costs.
• The company has incurred losses since its inception and has not generated sufficient cash flows from operations, raising substantial doubt about its ability to continue as a going concern.
• Significant related party liabilities, including $3,658,382 within the working capital deficiency, and $2,919,330 in total accrued Preferred D Stock dividends as of December 31, 2025.
• A $300,000 term note to EuroAmerican Investment Corp., with $569,030 in accrued interest, matures on June 30, 2026, and its extension is uncertain.
• The company's board lacks independent directors, and the audit committee is composed of the entire board, leading to a material weakness in internal controls.

Risks

• Going Concern Risk: The company has incurred losses since inception, has not generated sufficient cash flows from operations, and has a significant working capital deficiency, raising substantial doubt about its ability to continue as a going concern.
• Funding Risk: The company may not have sufficient cash to meet its needs through March 31, 2027, and relies on its largest shareholder, Fountainhead, for working capital funding, which is not guaranteed. There is no assurance that additional equity or debt funding will be available on acceptable terms or at all.
• Debt Maturity Risk: A term note for $300,000 to EuroAmerican Investment Corp., with $569,030 in accrued interest, matures on June 30, 2026, and its extension is uncertain. Failure to extend or repay could severely impact liquidity.
• Market Volatility and Illiquidity: The market price of common stock is highly volatile and subject to illiquidity, typical for early-stage medical device companies.
• Product Liability and Professional Liability: The company is exposed to risks related to product liability for Vycor Medical and professional liability for NovaVision.
• Regulatory Compliance: The company operates in a highly regulated industry and must maintain various regulatory certifications and approvals (e.g., FDA, CE Marking, Health Canada MDL).
• Cybersecurity Threats: While policies are in place, the company is still exposed to potential unauthorized occurrences on or through its information systems that could affect confidentiality, integrity, or availability of information.
• Dependence on Key Manufacturers: Purchases from three sub-contract manufacturers each represent over 10% of total annual purchases, indicating a concentration risk.
• Related Party Dependence: Significant financial relationships with related parties (Fountainhead, Peter Zachariou) for funding and debt, which may not always be available or on favorable terms.
• Internal Control Weakness: Lack of a functioning audit committee with independent members results in ineffective oversight of internal controls, which could lead to material misstatements in financial statements.
• Discontinued Operations Wind-down: Ongoing minor costs and potential German tax liability related to the wind-down of NovaVision GmbH.

Future Outlook

The company is continuing to execute a plan to achieve revenue growth, focusing on increasing market penetration and international growth for Vycor Medical, and new product development. For NovaVision, the strategy involves partnering with entities for distribution, particularly in digital health, and exploring alternatives such as licensing, merger, or sale. The company believes it may not have sufficient cash to meet its needs through March 31, 2027, without obtaining additional debt or equity funding, which is not assured.

Management Comments

• "We believe that the most efficient way to tackle the distribution of NovaVision's patient and professional products is by partnering with entities that have either direct access to the end users or the technological capability to leverage the NovaVision therapy platform, particularly in digital health and into non-medical areas."
• "Management is also open to a broad range of alternatives for NovaVision as a whole, which could comprise distribution and marketing partnerships, licensing, merger or sale."
• "The Company believes it may not have sufficient cash to meet its various cash needs through March 31, 2027 unless the Company is able to obtain additional cash from the issuance of debt or equity securities."
• "Fountainhead, the Company's largest shareholder, has provided working capital funding to the Company on an as-needed basis, although there is no guarantee that this will continue to be the case."

Industry Context

StockSavvy.ai notes that Vycor Medical operates in the competitive medical device industry, specifically neurosurgery and vision rehabilitation. The company's strategy to leverage existing distribution networks for Vycor Medical and seek partnerships or divestiture for NovaVision reflects a common industry trend among smaller players to optimize resource allocation and focus on core strengths or seek strategic exits for non-core assets. The emphasis on digital health partnerships for NovaVision aligns with the broader healthcare industry's shift towards technology-enabled patient care and remote therapies. The company's growth in international markets, particularly Europe, for its VBAS system indicates a successful expansion strategy in a globalized medical device market.

Comparison to Industry Standards

• The company's gross margins for Vycor Medical (83%) and NovaVision (93%) are generally strong for medical device companies, indicating good pricing power or efficient cost of goods sold. However, the decline in Vycor Medical's gross margin due to higher production and shipping costs suggests potential supply chain or scaling challenges that larger, more established medical device companies like Medtronic or Stryker might manage more efficiently through economies of scale.
• The significant working capital deficiency and reliance on related party funding for going concern raise red flags compared to industry standards, where financially stable companies typically maintain positive working capital and diverse funding sources. Companies like Johnson & Johnson or Siemens Healthineers, for instance, have robust balance sheets and access to capital markets without such going concern warnings.
• The lack of independent directors and a functioning audit committee is a significant corporate governance weakness, falling short of best practices and regulatory expectations for publicly traded companies, especially when compared to larger, well-governed peers.
• The strategy to seek partnerships or divest NovaVision is a common approach for smaller companies to unlock value or streamline operations, similar to how larger pharmaceutical companies might divest non-core therapeutic areas.

Corporate Governance

Legal Proceedings

• No material litigation, claims, or suits whose outcome could have a material effect on financial statements.
• Potential German tax liability of €75,000 (approximately $82,000) plus €12,000 (approximately $13,200) interest for the 2010 fiscal year related to NovaVision GmbH, which has been appealed and suspended, with no provision made as of December 31, 2025.

Related Party Transactions

• Accrued interest on related party loans of $50,283 in 2025 and $50,013 in 2024.
• Paid accrued interest on related party loans of $15,000 in 2025 and $35,140 in 2024.
• Accrued $324,370 of Preferred D Stock dividends in both 2025 and 2024.
• Total accrued Preferred D Stock dividends at December 31, 2025, was $2,919,330, with $2,034,332 regarding Fountainhead Capital Management Limited and $750,473 regarding Peter Zachariou.
• Promissory notes to Peter Zachariou for $30,000, bearing 10% interest, due June 25, 2026, or on demand.
• Fifteen promissory notes to Fountainhead Capital Management Limited for $463,373, bearing 10% interest, due between April 2026 and March 2027, or on demand.
• Fountainhead Capital Management Limited owned 60.95% of Common Stock and 69.69% of Series D Preferred Stock at December 31, 2025.
• Peter C. Zachariou owned 0.15% of Common Stock and 25.71% of Series D Preferred Stock at December 31, 2025.

Stakeholder Impact

• Shareholders: Face significant dilution risk if new equity is issued, and potential loss of investment due to going concern doubts. Common stock is highly volatile and illiquid. Preferred D stockholders have accrued significant dividends ($2,919,330) which are not being paid in cash.
• Employees: The company has only 7 employees, and the going concern risk could impact job security.
• Creditors: Related party creditors (Fountainhead, Peter Zachariou) hold significant debt and accrued interest/dividends. The EuroAmerican Investment Corp. note is a substantial liability. The ability to repay these obligations is uncertain given the going concern warning.
• Customers: Continued product development and market penetration for Vycor Medical could benefit customers, but financial instability could pose long-term supply or support risks. NovaVision's strategy of partnering or selling could change service delivery.
• Suppliers: Concentration risk with three sub-contract manufacturers could lead to supply chain vulnerabilities if the company's financial health deteriorates.

Next Steps

• Increase market penetration in the US for Vycor Medical.
• Increase international growth in under-represented territories for Vycor Medical.
• Continue new product development for Vycor Medical.
• Add products complementary to VBAS, leveraging existing distribution network.
• Partner with entities for NovaVision distribution, especially in digital health and non-medical areas.
• Explore broad alternatives for NovaVision, including licensing, merger, or sale.
• Address the maturity of the EuroAmerican Investment Corp. term note by June 30, 2026.
• Seek additional equity or debt funding to address liquidity concerns and going concern risk.
• Formally wind down NovaVision GmbH in Germany.
• Evaluate the impact of ASU No. 2024-03 (Expense Disaggregation Disclosures) for adoption on January 1, 2027.
• Evaluate the impact of ASU 2025-05 (Credit Losses for Accounts Receivable and Contract Assets) for adoption after December 15, 2025.

Key Dates

Recommendation

The filing explicitly states "substantial doubt regarding our ability to continue as a going concern," which is a critical red flag for investors. The worsening working capital deficit, negative operating cash flow, and significant reliance on related party funding with no guarantee of continuation highlight severe liquidity issues. While revenue growth in one segment is positive, it is overshadowed by the fundamental financial instability and corporate governance weaknesses (lack of independent audit committee). The upcoming maturity of a significant related-party note without certainty of extension adds further immediate risk. These factors collectively indicate a high probability of significant share price decline and potential loss of investment.

Keywords

Medical Devices, Neurosurgery, Vision Rehabilitation, Stroke Recovery, Brain Injury Therapy, FDA Clearance, CE Marking, ISO 13485, Going Concern, Working Capital Deficiency, SEC Filing, 10-K, Vycor Medical, NovaVision, Medical Technology, Financial Reporting, Corporate Governance